Neurocrine Stock Soars 14%, Adding $2 Billion, After Sales Top $1 Billion And Ingrezza Outlook Rises

Crenessity sales more than doubled and the Ingrezza forecast moved up, while a new Vykat patient death raised the reported toll to eight.

Share
Neurocrine Stock Soars 14%, Adding $2 Billion, After Sales Top $1 Billion And Ingrezza Outlook Rises

Neurocrine Biosciences, the San Diego drugmaker, saw its shares climb 13.56% to $165.06 in Tuesday trading as of 10:05 a.m. ET, adding about $2 billion in market value. Revenue grew 41% to $1.1 billion. It also raised its 2026 Ingrezza forecast, even as safety questions about its newly acquired Vykat drug lingered.

Crenessity doubles, Ingrezza adds 17%

Crenessity sales more than doubled to $211 million. Ingrezza reached $801 million, and the 2026 Ingrezza outlook now stands at $2.9 billion to $2.925 billion.

Adjusted third-quarter profit came to $347 million, up from $222 million a year earlier, according to the company's filing. The quarter was the company's first with more than $1 billion in net product sales.

Neurocrine develops and sells drugs across neurology, psychiatry, endocrinology and immunology. Its approved products treat tardive dyskinesia, Huntington's chorea and classic congenital adrenal hyperplasia, a rare hormone disorder. Ingrezza net product sales were $2.51 billion for 2025, and Crenessity sales were $301.2 million.

Vykat's safety record and the Soleno deal

The quarter also carried $107 million in sales of Vykat XR. A newly confirmed patient death brought the reported toll to eight, BioSpace reported.

Neurocrine bought Vykat through its $2.9 billion acquisition of Soleno Therapeutics in April, so the drug's safety record bears directly on what that deal delivers. The company plans a new study in 2027 on dosing and safety in Prader-Willi patients with complex health issues.

A rally against a lagging year

The stock was on pace for its biggest one-day gain in at least 275 trading sessions, the last comparable one coming on Sept. 30, 2025.

As of Monday's close, the shares were up about 3% year to date, trailing the S&P 500's gain of about 10%. They sat 22% below their highest close of the past year, set on July 30.

Neurocrine's 2027 study of Vykat dosing and safety in Prader-Willi patients with complex health issues is the next marker for the drug.

Sources

More on Neurocrine Biosciences

All Neurocrine Biosciences (NBIX) coverage →